The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

NICE news for life sciences Every 2 months Our latest news and updates for those working within the life sciences sector. Subscribe for information on: our work to improve patient access to innovative ...

In development [GID-TA11183] Expected publication date: 02 July 2025 ...

08 July 2025 via Zoom Final Agenda The meeting will take place via Zoom, a secure web conferencing tool. The meeting will run from 9:00am although this may be subject to change. Joining links and ...

Our updated guideline reflects this change in practice and in doing so they recommend an earlier use of the SGLT2 inhibitors empagliflozin and dapagliflozinthan we’ve recommended before. It means they ...

Help make a difference on behalf of the people most affected by our recommendations. The voluntary and community sector forum brings together organisations who want to inform and shape our work. It’s ...

Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age. Last reviewed: 16 April 2025 Next review: This ...

Given as a twice-a-day tablet, capivasertib is a targeted treatment called a kinase inhibitor. It works by blocking the action of an abnormal protein that tells cancer cells to multiply. This helps ...

Final guidance published today recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma when ...

Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults. Last ...